Though the vote was unanimous, discussions were complicated by the diversity of JN.1 viruses.
FDA panel supports switch to JN.1 for fall COVID vaccines
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows